（华润三九公告） 益气清肺颗粒于2025年1月获得国家药品监督管理局颁发的《药品注册证书》，并正在进行上市后的学术推广和挂网 销售等相关工作。 近日，华润三九发布公告称，公司的药品益气清肺颗粒通过谈判首次纳入《国家基本医疗保险、生育保险和工伤保险 药品目录（2025年）》。该药品的注册分类为中药3.2类，剂型为颗粒剂，协议有效期为2026年1月1日至2027年12月31 日，适应症为益气养阴，健脾和中，清热祛湿。 ...

Core Viewpoint - China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. has successfully negotiated to include its product Yiqi Qingfei Granules in the National Medical Insurance Directory (2025 version), which is expected to enhance the company's product portfolio in the respiratory field and strengthen its market position [1][3]. Product Information - Product Name: Yiqi Qingfei Granules - Drug Classification Code: ZA09G - Drug Type: Traditional Chinese Medicine (TCM) - Registration Category: TCM Class 3.2 - Dosage Form: Granules - Agreement Validity: January 1, 2026, to December 31, 2027 - Indications: Used for symptoms related to Qi and Yin deficiency, spleen deficiency, and dampness, including fatigue, shortness of breath, dry cough, and gastrointestinal discomfort [1][2]. Impact on the Company - Yiqi Qingfei Granules received its drug registration certificate from the National Medical Products Administration in January 2025 and is currently undergoing post-market academic promotion and sales activities. The inclusion in the National Medical Insurance Directory is expected to have a positive impact on the company's product layout in the respiratory field, although it is not anticipated to significantly affect short-term operating performance [3].

最新公告列表 近日，华润三九医药股份有限公司发布公告称，其药品益气清肺颗粒通过谈判首次纳入《国家基本医疗 保险、生育保险和工伤保险药品目录（2025年）》。该药品为中药3.2类，适应症为疫病后短期症状属 气阴两虚、脾虚失运、余邪未尽证。益气清肺颗粒于2025年1月获批上市，目前正在开展上市后学术推 广和挂网销售。纳入国家医保目录自2026年1月1日起执行，协议有效期至2027年12月31日。公告显示， 预计对公司短期经营业绩不构成重大影响，但有助于完善呼吸领域产品布局。 截至2025年12月8日收盘，华润三九（000999）报收于28.15元，较前一交易日下跌0.49%，最新总市值 为468.48亿元。该股当日开盘28.3元，最高28.39元，最低28.1元，成交额达2.25亿元，换手率为0.48%。 《关于公司产品通过谈判首次纳入国家医保目录的公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

上证报中国证券网讯（记者 王乔琪）华润三九12月8日晚间公告，公司药品益气清肺颗粒首次纳入《国 家医保目录》（2025版）。 来源：上海证券报·中国证券网 据悉，益气清肺颗粒于2025年1月获得国家药品监督管理局颁发的《药品注册证书》，正式获批上市。 目前，益气清肺颗粒正在有序开展上市后学术推广和挂网销售等相关工作。 来源：上海证券报·中国证券网 上证报中国证券网讯（记者 王乔琪）华润三九12月8日晚间公告，公司药品益气清肺颗粒首次纳入《国 家医保目录》（2025版）。 据悉，益气清肺颗粒于2025年1月获得国家药品监督管理局颁发的《药品注册证书》，正式获批上市。 目前，益气清肺颗粒正在有序开展上市后学术推广和挂网销售等相关工作。 ...

公告显示，益气清肺颗粒于2025年1月获得国家药品监督管理局颁发的《药品注册证书》，正式获批上 市。适应症为益气养阴，健脾和中，清热祛湿，适用于疫病后短期症状，气阴两虚，脾虚失运，余邪未 尽证，症见倦怠乏力、动后气短、干咳少痰、咽喉不利、胃脘痞闷、纳呆便溏，舌淡或红、少津，脉细 数。 北京商报讯（记者 王寅浩 宋雨盈）12月8日，华润三九发布公告称，公司药品益气清肺颗粒通过谈判首 次纳入《国家基本医疗保险、生育保险和工伤保险药品目录（2025年）》，协议有效期为2026年1月1日 至2027年12月31日。 ...

Core Viewpoint - China Resources Sanjiu Pharmaceutical Co., Ltd. has successfully included its product Yiqi Qingfei Granules in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025 version) through negotiations, which is expected to enhance the company's product portfolio in the respiratory field and strengthen its market leadership position [1] Group 1 - Yiqi Qingfei Granules received the drug registration certificate from the National Medical Products Administration in January 2025 and is currently undergoing post-market academic promotion and online sales [1] - The 2025 version of the National Medical Insurance Catalog will officially take effect on January 1, 2026, marking the first inclusion of Yiqi Qingfei Granules in this catalog [1] - The short-term impact on the company's operating performance is not expected to be significant, but the inclusion is seen as a positive step for the company's strategic positioning in the respiratory product sector [1]

Core Viewpoint - China Resources Sanjiu (000999.SZ) announced that its drug Yiqi Qingfei Granules has been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog for 2025 through negotiations [1] Group 1 - The inclusion of Yiqi Qingfei Granules marks a significant milestone for the company, enhancing its market access and potential revenue streams [1] - This decision is part of a broader initiative by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security to update the drug catalog [1]

华润三九（000999）(000999.SZ)公告，据国家医保局、人力资源社会保障部关于印发《国家基本医疗 保险、生育保险和工伤保险药品目录》以及《商业健康保险创新药品目录》的通知，公司药品益气清肺 颗粒通过谈判首次纳入《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》。 ...

益气清肺颗粒于2025年1月获得国家药品监督管理局颁发的《药品注册证书》，正式获批上市。目前， 益气清肺颗粒正在有序开展上市后学术推广和挂网销售等相关工作。《国家医保目录》（2025版）自 2026年1月1日起正式执行，该药品首次纳入《国家医保目录》（2025版），预计对公司短期的经营业绩 不构成重大影响，对完善公司呼吸领域产品布局、强化公司品类领导地位具有积极作用。 格隆汇12月8日丨华润三九(000999.SZ)公布，根据国家医保局、人力资源社会保障部关于印发《国家基 本医疗保险、生育保险和工伤保险药品目录》以及《商业健康保险创新药品目录》（2025年）的通知 （医保发〔2025〕33号），华润三九医药股份有限公司药品益气清肺颗粒通过谈判首次纳入《国家基本 医疗保险、生育保险和工伤保险药品目录（2025年）》。 ...

Core Viewpoint - The National Healthcare Security Administration (NHSA) has released the new basic medical insurance drug list for 2025, which will take effect on January 1, 2026, leading to a significant increase in the success rate of new drug negotiations, particularly for innovative drugs with high clinical value [1][2]. Group 1: New Drug Negotiation Success - The success rate for new drug negotiations in 2025 has significantly improved to 88%, up from 76% in 2024, with 114 new drugs added to the national medical insurance drug list, including 50 Class 1 innovative drugs [2][3]. - The total number of drugs in the national medical insurance drug list has increased to 3,253, enhancing coverage for critical areas such as cancer, chronic diseases, mental health, rare diseases, and pediatric medications [2]. Group 2: Unique Drug Inclusion - Among the 114 newly added drugs, 105 are unique varieties, representing 92.11% of the total, including 98 Western medicines and 7 traditional Chinese medicines [3]. - The inclusion of unique traditional Chinese medicines from companies like China Resources Sanjiu, Yiling Pharmaceutical, and others indicates a balanced representation in the new drug list [3]. Group 3: Market Potential and Growth - The inclusion of 116 drugs in the latest negotiation, particularly 11 new drugs from Heng Rui Medicine and others, is expected to lead to rapid market share growth and product volume increase due to their entry into the medical insurance directory [4][5]. - The negotiation also included new mechanism drugs, such as antibody-drug conjugates and small nucleic acid siRNA drugs, which are anticipated to drive market penetration and accessibility [5]. Group 4: Commercial Health Insurance Directory - The first commercial health insurance innovative drug directory saw intense competition, with 121 candidates but only 24 entering negotiations, resulting in 19 drugs being successfully included [6]. - The directory covers critical diseases such as Alzheimer's and multiple myeloma, with a balanced mix of imported and domestic drugs [6]. Group 5: Investment Recommendations - Companies with a significant number of innovative drugs included in the new medical insurance directory, such as Heng Rui Medicine, BeiGene, and others, are recommended for investment [9]. - Potential growth in traditional Chinese medicine products included in the new directory, such as those from China Resources Sanjiu and Yiling Pharmaceutical, is also highlighted [9].